Danco Urges Supreme Court to Revoke Mail‑Order Ban on Abortion Pill

Danco Laboratories has asked the U. S. Supreme Court to reverse a recent appeals court decision that halted the delivery of mifepristone, an abortion medication, through mail services. The ruling came from a conservative three‑judge panel that agreed with Louisiana’s complaint that the FDA’s 2023 rule—allowing the drug to be shipped—failed to adequately address serious health risks such as sepsis and heavy bleeding. The court’s order is only temporary but marks a major setback for patients nationwide, especially in states that prohibit abortion. The company argues that the injunction creates chaos at a time when quick medical decisions are crucial, forcing doctors, pharmacies and patients to guess what is permissible. Danco’s request highlights the growing legal battle over how easily abortion pills can be accessed, following a 2000 approval and later FDA relaxations that removed the requirement for in‑person pickup.In states where abortion is legal and telehealth prescriptions are allowed, less than two percent of abortion drug orders are filled face‑to‑face. The FDA’s removal of the in‑person rule has thus made remote access far more common. Both Danco and GenBioPro have stepped into Louisiana’s lawsuit to defend the FDA regulation, with Danco’s only product being the branded mifepristone called Mifeprex. The Supreme Court earlier this year rejected a similar challenge by medical groups, citing lack of standing, and the case is now being handled in Missouri, Kansas and Idaho. A federal judge had paused Louisiana’s lawsuit while the Trump administration reviewed mifepristone safety, a review that has stalled until after November’s midterm elections. The judge denied Louisiana’s request to block the 2023 rule but indicated he would find it unlawful when the case returns. The outcome of Danco’s appeal could determine whether patients in restrictive states will regain the ability to receive abortion medication by mail, a decision that has profound implications for reproductive health rights across the country.